SCHEMBL21045860

SCHEMBL21045860

COc1cc(C(=O)N2CCC(c3cnc(N)cc3OC)CC2)ncc1OCC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPC6 Q9Y210 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29774007 1.00 TRPC6 (1.00) TRPC6
Trifluoroacetic Acid SCHEMBL21045859 0.94 TRPC6 (0.88) TRPC6
SCHEMBL21045732 0.90 TRPC6 (1.00) TRPC6
SCHEMBL21045920 0.90 TRPC6 (1.00) TRPC6
SCHEMBL21045729 0.90 TRPC6 (1.00) TRPC6
SCHEMBL26458400 0.89 TRPC6 (0.81) TRPC6
SCHEMBL21045698 0.89 TRPC6 (1.00) TRPC6
SCHEMBL21045865 0.88 TRPC6 (1.00) TRPC6
SCHEMBL23047372 0.87 TRPC6 (0.82) TRPC6
SCHEMBL21045821 0.87 TRPC6 (1.00) TRPC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49699-E1 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-17 US claimed
US-20230149393-A1 INHIBITORS OF TRPC6 FOR TREATING RESPIRATORY CONDITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-05-18 US claimed
EP-3700902-B1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INT (DE) 2023-03-08 EP claimed
US-20210163449-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-06-03 US claimed
WO-2021079962-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS 国立大学法人大阪大学 2021-04-29 WO claimed
US-10800757-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-13 US claimed
US-20190169167-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019-06-06 US claimed
EP-4103245-B1 ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES KLINIKUM DER TECHNISCHEN UNIV MUENCHEN TUM KLINIKUM (DE) 2026-04-01 EP disclosed
US-20250057829-A1 INHIBITORS OF TRPC6 FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-02-20 US disclosed
US-20240408087-A1 TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-12-12 US disclosed
US-RE49699-E1 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-17 US disclosed
US-RE49699-E1 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-17 US disclosed
US-RE49699-E1 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-17 US disclosed
US-10889568-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-01-12 US disclosed
US-10800757-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-13 US disclosed
US-10800757-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-13 US disclosed
US-20190169168-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-06 US disclosed
US-20190169168-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-06 US disclosed
US-20190169167-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019-06-06 US disclosed
US-20190169167-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149393-A1 INHIBITORS OF TRPC6 FOR TREATING RESPIRATORY CONDITIONS TRPC6, TRPV6, NHERF1 TRPC6 1/4885
US-20190169168-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC7 TRPC6 1/4885
US-20210163449-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC7 TRPC6 1/4885
US-10889568-B2 Inhibitors of TRPC6 TRPC6, TRPC1, TRPC7 TRPC6 1/4885
US-20240408087-A1 TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS TRPC6, TRPC1, TRPC3 TRPC6 1/4885
US-20190169167-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC7 TRPC6 1/4885
US-20250057829-A1 INHIBITORS OF TRPC6 FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS TRPC6, REN, TRPC1 TRPC6 1/4885
US-10800757-B2 Inhibitors of TRPC6 TRPC6, TRPC1, TRPC7 TRPC6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.